Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 55

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 55
---
 |     | Cecilia Jones, our chief financial officer; |

| • |     | James Burns, our chief legal officer; |

| • |     | Sarah Gheuens, M.D., Ph.D., our chief medical officer, head of research & development; and |

| • |     | Tsveta Milanova, our chief commercial officer. |

Say-on-Pay Vote Support and Stockholder Engagement At our 2024 annual meeting of stockholders, we conducted a non-binding advisoryvote on the compensation of our NEOs, commonly referred to as a “say-on-pay” vote,in accordance with the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. Approximately 94% of the votes cast by stockholders on this proposal, excluding broker non-votes, werecast in support of the compensation paid to our named executive officers in 2023. While this vote is a non-binding advisoryvote, our compensation & people committee and board of directors take the voting results into account in determining the compensation of our NEOs. In light of the strong level of support evidenced by last year’s say-on-pay vote,among other factors, our compensation & people committee decided to maintain our general approach to executive compensation and made no significant changes to our executive compensation program in 2024. Our compensation & people committee and board of directors will continue to consider stockholder input and monitor our executive compensation program to ensure it aligns the interests of our executive officers with the interests of our stockholders and adequately addresses input from our stockholders. Executive Summary Agios had a transformative year in 2024. We made significant progress on key milestones for our PYRUKYND ®(mitapivat) franchise. In January 2024, we announced topline data for ENERGIZE, our phase 3 pivotal trial of PYRUKYND ®in adults with non-transfusion-dependentalpha- or beta-thalassemia, which demonstrated that the study met its primary endpoint of hemoglobin response. In the ENERGIZE trial, treatment with PYRUKYND ®also demonstrated statistically significant improvements compared to placebo for both key secondary endpoints: change in baseline in FACIT-Fatigue score and hemoglobin concentration. In June 2024, 40

we announced topline data from ENERGIZE-T, our phase 3 study of PYRUKYND in adults with transfusion-dependent alpha- or beta-thalassemia, which met its primary endpoint of transfusion